ストックスクリーナーアプリを入手
6.77
8.39%
-0.62
前日終値:
$7.39
開ける：
$7.33
24時間の取引高:
684.49K
Relative Volume:
13.81
時価総額：
$574.58M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-12.65%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$6.76
$7.33
1週間の範囲:
$6.76
$7.9999
52週間の値動き範囲:
$6.76
$7.9999
Niagen Bioscience Inc Stock (NAGE) Company Profile
NAGE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
6.77 | 574.58M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-08-16 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-08-11 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | 開始されました | ROTH Capital | Buy |
| 2019-10-16 | 開始されました | Oppenheimer | Outperform |
| 2019-02-14 | 開始されました | B. Riley FBR | Buy |
| 2017-11-27 | 再開されました | H.C. Wainwright | Buy |
| 2017-09-25 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-01-03 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
Niagen Bioscience Inc (NAGE) 最新ニュース
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE) - Yahoo Finance
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - Marketscreener.com
Niagen Bioscience broadens NAD+ precursor IP portfolio with new patent - TipRanks
Niagen Bioscience secures new patent for NAD+ precursors - Investing.com
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms - Business Wire
Niagen Bioscience, Inc. Rings the Closing Bell - Nasdaq
ChromaDex Completes Name Change to Niagen Bioscience -March 19, 2025 at 09:29 am EDT - Marketscreener.com
Chromadex Rebrands to Niagen Bioscience, Inc. - TipRanks
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science - The Bakersfield Californian
ChromaDex changes name to Niagen Bioscience to home in on healthy aging - SupplySide Supplement Journal
Chromadex’s Strategic Rebranding and Promising Clinical Developments Justify Buy Rating - TipRanks
ChromaDex Changing Name To Niagen Bioscience While Shifting Focus To Rx NAD+ - HBW Insight
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Bluefield Daily Telegraph
ChromaDex to rebrand as Niagen Bioscience and change ticker - Investing.com
Healthy Aging Leader ChromaDex Takes Center Stage at ROTH Conference Longevity Panel - StockTitan
ChromaDex Capitalizes On Longevity Boom, But Valuation Remains High - Seeking Alpha
ChromaDex Reports Strong 2024 Financial Performance - TipRanks
When Will ChromaDex Reveal Its Q4 Performance? Key Date for NAD+ Leader's Financial Results - StockTitan
ChromaDex to Present at Lytham Partners Healthcare Summit, Showcasing NAD+ Research Advances - StockTitan
Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide - Business Wire
Thorne acquires brain health formula partner in $5 million deal - SupplySide Supplement Journal
The proper role of pre-blends of nutrients in production of dietary supplements - SupplySide Supplement Journal
FDA Criminal Office Said to Be Examining Drug Ostarine in Dietary Supplements - SupplySide Supplement Journal
Technology disruption in the dietary supplement industry - SupplySide Supplement Journal
IV and Injection Offerings to Additional Leading Wellness Clinics - Business Wire
GMP Requirements for Softgels - SupplySide Supplement Journal
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions - Business Wire
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) - Business Wire
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award - Business Wire
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - Business Wire
is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program - Business Wire
ChromaDex sides with FDA, pharma in NMN supplements debate - SupplySide Supplement Journal
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen - Business Wire
Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ - PR Newswire
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR) - BioSpace
ChromaDex and Zesty Paws team up on cellular health for dogs - Longevity.Technology
(Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD - Business Wire
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line - Business Wire
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NM - Business Wire
ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness - Business Wire
Better gummies with Chelamax® magnesium – infographic - SupplySide Supplement Journal
Transcript : ChromaDex Corporation, Q1 2023 Earnings Call, May 10, 2023 - Marketscreener.com
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States - Business Wire
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards - Business Wire
How This Global Bioscience Company Got Innovative With Research And Saved Millions - Forbes
ChromaDex and Nestlé Health Science Announce New Niagen - Business Wire
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen - Business Wire
Longevity supplements report: ChromaDex profile - Longevity.Technology
Exclusive: ChromaDex’s CEO on Longevity commercialisation - Longevity.Technology
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College - Business Wire
Niagen Bioscience Inc (NAGE) 財務データ
Niagen Bioscience Inc (NAGE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Niagen Bioscience Inc (NAGE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):